A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 Planned initiation date changed from 18 Jun 2017 to 13 Jul 2017.
- 30 May 2017 Planned initiation date changed from 25 Apr 2017 to 18 Jun 2017.